MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • MDS Virtual Congress 2021

    The mitochondrial targeted drug SBT-272 attenuates dopaminergic neuron loss, alpha-synuclein burden and neuroinflammation in a mouse model of Parkinson’s Disease

    S. Bido, J. Kūka, M. Makrecka-Kuka, G. Zheng, D. Keefe, V. Broccoli (Milan, Italy)

    Objective: To assess the preclinical efficacy of the investigational drug SBT-272 in a mouse model of Parkinson’s Disease (PD). Background: SBT-272 is a peptidomimetic drug…
  • MDS Virtual Congress 2021

    Methylation status of SNCA gene in multiple system atrophy and Parkinson’s disease

    E. Iakovenko, N. Abramycheva, E. Fedotova, S. Illarioshkin (Moscow, Russian Federation)

    Objective: Parkinson’s disease (PD) and multiple system atrophy (MSA) are classical synucleinopathies caused by misfolding of alpha-synuclein protein. Clinical picture of PD and MSA in…
  • MDS Virtual Congress 2021

    Validation of the Neuroprotective Potential of SLP-2 against alpha-synuclein neuropathology in a Mouse Model of Parkinson’s Disease

    C. Bolduc, M. Lorente Picón, S. Laouafa, J. Soliz, I. Pichler, M. Lévesque (Québec, Canada)

    Objective: We aim to validate the neuroprotective potential of SLP-2 against α-syn neuropathology and neurodegeneration of dopaminergic neurons in a mouse model of Parkinson’s disease.…
  • MDS Virtual Congress 2021

    α-Synuclein in sympathetic nerve fibers distinguishes PRKN from LRRK2 and other genetic forms of Parkinson’s Disease

    R. Isonaka, D. Goldstein, W. Zhu, E. Yoon, D. Ehrlich, A. Schindler, A. Kokkinis, M. Sabir, S. Scholz, S. Bandres-Ciga, C. Blauwendraat, P. Gonzalez-Alegre, G. Lopez, E. Sidransky, D. Narendra (Bethesda, USA)

    Objective: This cross-sectional observational study compared magnitudes of intra-neuronal deposition of α-synuclein in common and rare genetic forms of Parkinson’s disease. Background: Cytoplasmic inclusions of…
  • MDS Virtual Congress 2021

    ABBV-0805, a novel α-synuclein oligomer selective antibody, prolonged lifespan and prevented accumulation of α-synuclein pathology in mouse models of Parkinson’s disease

    J. Fälting, F. Eriksson, J. Sigvardson, M. Johannesson, A. Kasrayan, M. Jones-Kostalla, P. Appelkvist, L. Söderberg, M. Blom, A. Rachalski, K. Nordenankar, O. Zachrisson, E. Amandius, G. Osswald, M. Moge, M. Ingelsson, J. Bergström, L. Lannfelt, C. Möller, M. Giorgetti, E. Nordström (Stockholm, Sweden)

    Objective: We report on the pharmacological characteristics of ABBV-0805 (BAN0805), a monoclonal antibody that exhibits a high selectivity for human α-synuclein oligomers and very low…
  • MDS Virtual Congress 2021

    Gut dysbiosis in Parkinson’s disease with motor complications

    K. Takahashi, H. Nishiwaki, M. Ito, K. Iwaoka, K. Yamahara, K. Takahashi, Y. Suzuki, K. Taguchi, Y. Tsuboi, K. Kashihara, M. Hirayama, K. Ohno, T. Maeda (Shiwa, Japan)

    Objective: We aimed to identify gut dysbiosis in Parkinson's disease patients with motor complications. Background: Recently, several evidences suggest that the gut microbiota is associated…
  • MDS Virtual Congress 2021

    α-synuclein expression is not mediated by β2-adrenoreceptor modulation in human dopaminergic cells

    M. Langmyhr, IH. Flønes, CC. Cappelletti, C. Tzoulis, M. Toft (Oslo, Norway)

    Objective: Modulation of the β2-adrenoreceptor (also called the β2-adrenergic receptor or β2-adrenoceptor) has been reported to regulate SNCA expression. We sought to determine the expression…
  • MDS Virtual Congress 2021

    Integrated Multi-omics of the Gut Microbiome Reveal 2-Hydroxypyridine as a Novel Molecule Relevant to Parkinson’s Disease Pathogenesis

    V. Aho, JP. Trezzi, C. Jäger, S. Schade, C. Trenkwalder, A. Janzen, U. Heins-Marroquin, C. Linster, G. Gomez Giro, J. Schwamborn, T. Kitami, M. Thomas, K. Schmit, C. Martin-Gallausiaux, M. Buttini, M. Mittelbronn, W. Oertel, B. Mollenhauer, P. Wilmes (Esch-Sur-Alzette, Luxembourg)

    Objective: To search for molecular links between Parkinson’s disease (PD) pathogenesis and gut microbes based on integrated multi-omic analyses of fecal samples from patients with…
  • MDS Virtual Congress 2021

    The potential of GBA1 knock-out medaka as a model animal in the search for therapeutic compounds for GBA1-related α-synucleinopathy

    E. Nakanishi, M. Sawamura, Y. Taruno, N. Uemura, H. Yamakado, R. Takahashi (Kyoto, Japan)

    Objective: This study was performed to search for therapeutic agents for GBA1-related α-synucleinopathy. Background: The GBA1 gene is the causative gene of Gaucher’s disease (GD).…
  • MDS Virtual Congress 2021

    The role of amylin in Parkinson´s disease neurodegenerative process

    R. Bugallo, I. Martínez-Valbuena, I. Marcilla, MC. Caballero, A. Vilas-Zornoza, E. Guruceaga, JA. Sánchez-Arias, S. Ursua, A. Pérez-Mediavilla, MR. Luquin (Pamplona, Spain)

    Objective: We investigate the functional interaction between two amyloidogenic (amylin and synuclein) proteins as a potential mechanism for neurodegeneration in Parkinson disease (PD). Background: PD…
  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 60
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley